Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kully Woodruff

Internal Medicine New Bern, NC Medical Doctor

NPI 1750624813 CMS profile 3667156

3252 Wellons Blvd, New Bern, NC 28562

Open in the dashboard

General payments

$4,301

263 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kully Woodruff of New Bern, NC is reported in the CMS Open Payments database as having received $4,301 across 263 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $431 23
2024 General $1,531 97
2023 General $1,222 69
2022 General $869 57
2021 General $247 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kully Woodruff
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kully Woodruff were reported at $431. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kully Woodruff Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $247 $135 $37–$521 $132
2022 $869 $141 $42–$496 $149
2023 $1,222 $149 $45–$519 $160
2024 $1,531 $154 $47–$537 $164
2025 $431 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $911 61 payments
  2. Abbott Laboratories $426 28 payments
  3. Lilly USA, LLC $387 23 payments
  4. GlaxoSmithKline, LLC. $377 23 payments
  5. AbbVie, Inc. $292 16 payments
  6. Amgen Inc. $219 15 payments
  7. Otsuka America Pharmaceutical, Inc. $187 8 payments
  8. Merck Sharp & Dohme Corporation $154 8 payments
  9. Axsome Therapeutics, Inc. $152 9 payments
  10. Pfizer Inc. $145 9 payments
  11. Other $1,051 63 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,301 263 payments
Products named General payments · program years 2021–2025
  1. Ozempic $457 30 payments
  2. FreeStyle Libre 2 $426 28 payments
  3. RYBELSUS $413 27 payments
  4. TRELEGY ELLIPTA $348 21 payments
  5. MOUNJARO $263 15 payments
  6. Wegovy $234 17 payments
  7. REXULTI $187 8 payments
  8. ZEPBOUND $170 11 payments
  9. Repatha $152 10 payments
  10. Auvelity $152 9 payments
  11. Other $2,840 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 143 drugs

Part D claims

8,162

Median for Internal Medicine: 777

Drug cost

$720,197

Median for Internal Medicine: $73,373

Branded share of claims

23.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 97 $137,888
Eliquis Apixaban Brand 108 $94,581
Jardiance Empagliflozin Brand 60 $65,818
Farxiga Dapagliflozin Propanediol Brand 52 $60,189
Rybelsus Semaglutide Brand 18 $42,187
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 54 $39,787
Trulicity Dulaglutide Brand 33 $32,710
Januvia Sitagliptin Phosphate Brand 24 $29,209
Mounjaro Tirzepatide Brand 19 $22,429
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 23 $17,322

The 10 drugs with the highest cost, of 143 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$211,160

Of which drugs: $23,056

Medicare patients

376

Average age 74

Services billed

7,637

288 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 44%
Osteoporosis 35%
Depression 32%
Diabetes 24%
Chronic kidney disease 19%
Ischemic heart disease 18%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 125 130 $10,436
Pcv20 vaccine im 90677 Office 19 19 $5,504
Sarscv2 vac 30mcg trs-suc im 91320 Office 25 26 $3,826
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 11 11 $236

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $120
$120 54 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $110
$110 — —
Ozempic
  • Novo Nordisk Inc $101
$101 97 —
RYBELSUS
  • Novo Nordisk Inc $86
$86 18 —
Wegovy
  • Novo Nordisk Inc $77
$77 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record